Abbott secures CE Mark for blood glucose and ketone monitoring system

17 September 2013 (Last Updated September 17th, 2013 18:30)

US-based Abbott has received CE Marking in Europe for the FreeStyle Optium Neo blood glucose and ketone monitoring system, designed to track glucose trends and log insulin, which may help improve the patient's daily management of diabetes.

abbott

US-based Abbott has received CE Marking in Europe for the FreeStyle Optium Neo blood glucose and ketone monitoring system, designed to track glucose trends and log insulin, which may help improve the patient's daily management of diabetes.

The new icon-driven system features a sleek design and visual blood glucose trend indicators, which notify patients on both low and high-blood glucose levels.

The FreeStyle Optium Neo system also features an insulin dose feature, which allows healthcare professionals to programme a patient's insulin plan into the meter.

The meter allows patients to log actual insulin doses by simply tapping the arrows up or down according to the physician's recommendation in the dose guide.

This key feature allows patients and their healthcare professionals to review logged insulin doses along with glucose results.

Abbott diabetes care senior vice-president Heather Mason said: "The device's advanced design and technology enables the ability to track glucose trends and log insulin, which may help improve the patient's daily diabetes management."

Abbott's FreeStyle Optium Neo system is designed to be used with FreeStyle Optium blood glucose and ketone test strips; it is expected to be available throughout Europe within the next couple of months.

According to GlobalData estimates, diabetes care devices market in Europe was valued at $5.84bn in 2012 and is expected to grow at a CAGR of 5.4% to reach $8.47bn by 2019.


Image: Global headquarters in Abbott Park, Illinois, US. Photo: courtesy of Abbott.